Nationwide study of outpatient oral antimicrobial utilization patterns for children in Japan (2013-2016).
Adolescent
Anti-Infective Agents
/ administration & dosage
Antimicrobial Stewardship
Cephalosporins
/ administration & dosage
Child
Child, Preschool
Drug Prescriptions
/ statistics & numerical data
Drug Utilization
/ statistics & numerical data
Humans
Infant
Japan
Macrolides
/ administration & dosage
Outpatients
/ statistics & numerical data
Quinolones
/ administration & dosage
Retrospective Studies
Antimicrobial resistant microorganism
Antimicrobial use
Child
Database
Outpatients
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
25
07
2018
revised:
19
09
2018
accepted:
03
10
2018
pubmed:
7
11
2018
medline:
9
5
2019
entrez:
7
11
2018
Statut:
ppublish
Résumé
Antimicrobial resistance (AMR) is a major multinational public health concern. The Japanese government set goals in its AMR action plan to reduce use of oral cephalosporins, macrolides, and quinolones by half between 2013 and 2020. We aimed to evaluate antimicrobial use in children in Japan by observing prescription patterns as an interim assessment of the national AMR action plan. Using the national health claims database, we retrospectively analyzed all oral antimicrobials dispensed from outpatient pharmacies in Japan to children under 15 years old from 2013 to 2016 by age, prefecture, type of antimicrobial, and year. Data were presented as days of therapy (DOTs) per 1000 pediatric inhabitants per day (DOTs/PID). The χ A total of 721,627,553 oral antimicrobial DOTs were identified during 2013-2016. No statistically significant changes were observed in total antimicrobial use in children (2013: 28.54 DOTs/PID; 2016: 28.70 DOTs/PID; P The amount of antimicrobials prescribed to children in Japan is not decreasing. Overall antimicrobial prescriptions, as well as prescriptions of cephalosporins, macrolides, and quinolones, were most prevalent in children ≤5 years old. Rigorous antimicrobial stewardship interventions targeting infants and younger children are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Antimicrobial resistance (AMR) is a major multinational public health concern. The Japanese government set goals in its AMR action plan to reduce use of oral cephalosporins, macrolides, and quinolones by half between 2013 and 2020. We aimed to evaluate antimicrobial use in children in Japan by observing prescription patterns as an interim assessment of the national AMR action plan.
METHODS
METHODS
Using the national health claims database, we retrospectively analyzed all oral antimicrobials dispensed from outpatient pharmacies in Japan to children under 15 years old from 2013 to 2016 by age, prefecture, type of antimicrobial, and year. Data were presented as days of therapy (DOTs) per 1000 pediatric inhabitants per day (DOTs/PID). The χ
RESULTS
RESULTS
A total of 721,627,553 oral antimicrobial DOTs were identified during 2013-2016. No statistically significant changes were observed in total antimicrobial use in children (2013: 28.54 DOTs/PID; 2016: 28.70 DOTs/PID; P
CONCLUSION
CONCLUSIONS
The amount of antimicrobials prescribed to children in Japan is not decreasing. Overall antimicrobial prescriptions, as well as prescriptions of cephalosporins, macrolides, and quinolones, were most prevalent in children ≤5 years old. Rigorous antimicrobial stewardship interventions targeting infants and younger children are necessary.
Identifiants
pubmed: 30396820
pii: S1341-321X(18)30391-X
doi: 10.1016/j.jiac.2018.10.002
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Cephalosporins
0
Macrolides
0
Quinolones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22-27Informations de copyright
Copyright © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.